bioMérieux Vironostika
This article was originally published in The Gray Sheet
Executive Summary
Retrovirus firm will launch HIV-1 Plus O Microelisa system in late 2003 or early 2004 for qualitative detection of HIV-1 antibodies, including Group O, in serum and plasma, following earlier than expected CBER-reviewed PMA approval June 6. Yielding 100% sensitivity and specificity, the test is the first to gain approval since FDA requested a Type O diagnostic in 1996 (1"The Gray Sheet" July 22, 1996, I&W-11)...
You may also be interested in...
HIV screening test sensitivity to group O subtype to be required by FDA.
HIV SCREENING TEST GROUP O DETECTION CAPABILITY TO BE REQUIRED BY FDA, agency staffers say. The agency is still in the early stages of developing its policy on screening for the rare group O subtype of the HIV virus, but says it plans to revise HIV test lot release requirements to include detection of group O as well as group M, the predominant strain of HIV. FDA has not yet set a timetable for implementing the requirements.
Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.